Long-term safety concerns of antiresorptive therapy

Rheumatic Disease Clinics of North America

Volumn 37, Issue 3, 2011, Pages 387-400

  Zhang, Jie ^a   Saag, Kenneth G ^b   Curtis, Jeffrey R ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Anti resorptive therapy; Osteoporosis; Safety concerns

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; CANCER INCIDENCE; CARCINOGENESIS; CASE STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIAPHYSIS FRACTURE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGUS CANCER; ESOPHAGUS PERFORATION; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; FRAGILITY FRACTURE; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATHOGENESIS; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; ULCERATIVE ESOPHAGITIS; WOUND HEALING IMPAIRMENT;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 82455219356     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.08.001     Document Type: Review

References (53)

1. Devold H.M., Doung G.M., Tverdal A., et al. Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol 2010, 66(3):299-306.
2. Marx R.E. Uncovering the cause of "phossy jaw" Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed. J Oral Maxillofac Surg 2008, 66(11):2356-2363.
3. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011, 103(3):232-240.
4. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61(9):1115-1117.
5. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62(5):527-534.
6. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007, 65(3):369-376.
7. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
8. Favia G., Pilolli G.P., Maiorano E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 2009, 36(12):2780-2787.
9. Sedghizadeh P.P., Stanley K., Caligiuri M., et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009, 140(1):61-66.
10. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23(6):826-836.
11. Wilkinson G.S., Kuo Y.F., Freeman J.L., et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007, 99(13):1016-1024.
12. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006, 24(6):945-952.
13. Mavrokokki T., Cheng A., Stein B., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007, 65(3):415-423.
14. Lo J.C., O'Ryan F.S., Gordon N.P., et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010, 68(2):243-253.
15. Fellows J.L., Rindal D.B., Barasch A., et al. ONJ in two dental practice-based research network regions. J Dent Res 2011, 90(4):433-438.
16. Etminan M., Aminzadeh K., Matthew I.R., et al. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 2008, 35(4):691-695.
17. Barasch A., Cunha-Cruz J., Curro F.A., et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011, 90(4):439-444.
18. Novince C.M., Ward B.B., McCauley L.K. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs 2009, 189(1-4):275-283.
19. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25(11):2267-2294.
20. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90(3):1294-1301.
21. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358(12):1304-1306.
22. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury Feb 2008, 39(2):224-231.
23. Girgis C.M., Sher D., Seibel M.J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010, 362(19):1848-1849.
24. Koh J.S., Goh S.K., Png M.A., et al. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J Orthop Trauma 2010, 24(2):75-81.
25. Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26(3):553-560.
26. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21(3):399-408.
27. Dell R., Greene D., Ott S., et al. A retrospective analysis of all atypical femur fractures seen in a large california HMO from the Years 2007 to 2009. J Bone Miner Res 2010, 25(Suppl 1).
28. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364(18):1728-1737.
29. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24(6):1095-1102.
30. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362(19):1761-1771.
31. Kim S.Y., Schneeweiss S., Katz J.N., et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2010, [Epub ahead of print].
32. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20(8):1353-1362.
33. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305(8):783-789.
34. Lufkin E.G., Argueta R., Whitaker M.D., et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994, 4(6):320-322.
35. Maconi G., Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995, 90(10):1889-1890.
36. Ribeiro A., DeVault K.R., Wolfe J.T., et al. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998, 47(6):525-528.
37. Abraham S.C., Cruz-Correa M., Lee L.A., et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999, 12(12):1152-1157.
38. Famularo G., De Simone C. Fatal esophageal perforation with alendronate. Am J Gastroenterol 2001, 96(11):3212-3213.
39. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(1):89-90.
40. Pohl H., Sirovich B., Welch H.G. Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev 2010, 19(6):1468-1470.
41. Brown L.M., Devesa S.S., Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008, 100(16):1184-1187.
42. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97(2):142-146.
43. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789-1790. [author reply: 1791-2].
44. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789. [author reply: 1791-2].
45. Cardwell C.R., Abnet C.C., Cantwell M.M., et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304(6):657-663.
46. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
47. Nguyen D.M., Schwartz J., Richardson P., et al. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010, 55(12):3404-3407.
48. Rizzoli R., Akesson K., Bouxsein M., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22(2):373-390.
49. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
50. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350(12):1189-1199.
51. Schwartz A.V., Bauer D.C., Cummings S.R., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25(5):976-982.
52. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19(3):365-372.
53. Curtis J.R., Westfall A.O., Cheng H., et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008, 19(11):1613-1620.